Back

Real-world off-label Sacubitril/Valsartan dosing and clinical outcomes in patients with heart failure and end-stage kidney disease

31 August 2026 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Real-world cardiorenal therapeutics: outcomes and mechanisms in advanced kidney disease Renal Failure and Cardiovascular Disease ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Sung Il Im

kosin university gospel hospital, Pusan (Korea (Republic of))

8 More presentations in this session

Presentation thumbnail
Intradialytic hypertension drives right ventricular–pulmonary uncoupling: cardiac power index reveals energetic failure in haemodialysis
Doctor M. Merry (Ismailia, EG)
Abstract
Presentation thumbnail
Impact of cumulative contrast volume on medium- to long-term renal function in patients undergoing repeated percutaneous coronary interventions
Doctor P. Steinhoff (Bad Krozingen, DE)
Abstract
Presentation thumbnail
Incidence and predictors of echocardiographic cardiac deterioration after arteriovenous access surgery
Doctor L. Fisher (Ramat Gan, IL)
Abstract
Presentation thumbnail
Longitudinal change in epicardial adipose tissue attenuation on serial non-contrast chest CT in finerenone-treated patients: a real-world cohort study
Doctor X. Zhang (Xi'an, CN)
Abstract
Presentation thumbnail
CV inflammation prevalence and clinical biomarkers (hsCRP, IL-6 and NT-proBNP) levels in adults with ASCVD and CKD in KSA and UAE: Insights from the INFLAMEAST real‑world study
Doctor M. Alasnag (Jeddah, SA)
Abstract

Access the full session

Session thumbnail
Real-world cardiorenal therapeutics: outcomes and mechanisms in advanced kidney disease

The Event

Event poster

ESC Congress 2026

31 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Efficacy and safety of sacubitril-valsartan in heart failure with reduced ejection fraction in end-stage renal patients.
20 May 2023
thumbnail
Congress Session
Practical guidance to implement heart failure treatment with SGLT2 inhibitors in the outpatient setting
27 August 2023
thumbnail
Congress Presentation
Antiarrhythmic effect of Sacubitril-Valsartan: effects beyond reverse cardiac remodelling?
29 June 2021
thumbnail
ESC Journals
Real world evidence of Sacubitril/Valsartan in octogenarian patients with heart failure. Results From the PARACHUTE-HF Study
28 October 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources